Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

#4294

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Aim(s): Explain the EORTC QLQ and its merits in providing valid data. Give an overview of how the EORTC QLQ with GINET 21 demonstrate positive outcomes on patients’ quality of life.

Materials and methods: The data analytics are as follows: Which symptoms show the best improvement from pre-treatment to post-treatment (top 10)? Duration from first treatment to symptom response in each domain of questionnaire? Is there a difference in symptom response dependent on site of disease? Is there a difference in symptom response in those who are syndromic? From pre-treatment to post-treatment is there an overall improvement in quality of life?

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,